跳到主要內容

臺灣博碩士論文加值系統

(44.192.22.242) 您好!臺灣時間:2021/08/01 13:51
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:Sulidar Fitri
研究生(外文):Sulidar Fitri
論文名稱:Fenofibrate與第二型糖尿病之視網膜病變的關聯性
論文名稱(外文):The Association of Fenofibrate and The Risk of Retinopathy in Type 2 Diabetes
指導教授:陳玉菁陳玉菁引用關係
指導教授(外文):Yu - Ching, Chen
口試委員:胡文品朱彥煒陳玉菁
口試委員(外文):Wen-Pin,HuChu Y.W.Yu - Ching, Chen
口試日期:2012-07-23
學位類別:碩士
校院名稱:亞洲大學
系所名稱:生物與醫學資訊學系碩士班
學門:工程學門
學類:生醫工程學類
論文種類:學術論文
論文出版年:2012
畢業學年度:100
語文別:英文
論文頁數:52
中文關鍵詞:第二型糖尿病視網膜病變健保資料庫
外文關鍵詞:Type II DiabetesRetinopathyNational Health Insurance Database
相關次數:
  • 被引用被引用:0
  • 點閱點閱:467
  • 評分評分:
  • 下載下載:41
  • 收藏至我的研究室書目清單書目收藏:0
許多罹患了第二型糖尿病之患者未來有可能得到視網膜病變,因為視網膜病變是第二型糖尿病患者中常見之併發症。在台灣第二型糖尿病之發生率很高,因此罹患視網膜病變的患者不少;而糖尿病所引發之視網膜病變往往是導致具有工作能力者喪失視力之主因。而Fenofibrate是種可藉由降低脂質來控制體內脂肪的藥物。本研究利用台灣健康保險研究資料庫作研究,來了解fenofibrate藥物的使用與第二型糖尿病之視網膜病變發生之相關性。研究結果顯示HR=0.82,95%信賴區間為0.71到0.95。當調整研究對象之性別所得之HR為0.82,95%信賴區間為0.71到0.95,調整研究對象之年齡則HR為0.81,95%信賴區間為0.70到0.94;同時調整性別與年齡則HR為0.81,95%信賴區間為0.70到0.94。當HR的值小於1,表示有使用fenofibrate較沒有使用fenofibrate藥物之第二型糖尿病患者不容易罹患視網膜病變。
Retinopathy is the most common complication in type 2 diabetes. Many people usually will get diabetic retinopathy when they have diabetic type 2. In Taiwan the incidence of type 2 diabetes is high, so the retinopathy prone to happen in these persons and finally might lead to blindness in the productive age. Fenofibrate is a drug for lipid control by lowering the lipid. In this research, based on the data from National Health Insurance Research Database, I study the association of using fenofibrate and the risk of retinopathy in type 2 diabetes. The results are significant because 95%CI does not include 1 and the HR is less than one, so the risk of retinopathy is low. From adjusted variable of gender (HR=0.82; 95%CI= 0.71-0.95), age (HR=0.81; 95%CI= 0.70-0.94), sex and age (HR=0.81; 95%CI= 0.70-0.94) and for not adjusted variable it obtained (HR=0.82; 95%CI= 0.71-0.95).
COVER i
ACKNOWLEDGMENT ii
ENGLISH ABSTRACT iii
CHINESE ABSTRACT iv
TABLE of CONTENTS v
LIST of FIGURES vii
LIST of TABLES viii
LIST of ABREVIATIONS ix
CHAPTER ONE INTRODUCTION 1
1.1 Research Background and Motivation 1
1.2 Research Problem 2
1.3 Research Objectives 3
1.4 Procedure 3
1.5 The Importance of This Thesis 4
1.6 Structure of Thesis 4
CHAPTER TWO LITERATURE REVIEW 6
2.1 Diabetes Mellitus 6
2.2 Type 1 Diabetes 8
2.3 Type 2 Diabetes 8
2.4 Diabetic Retinopathy 10
2.5 Fenofibrate 12
2.6 NHIRD 14
2.7 Proc SQL in SAS to Retrieve the Data from NHIRD Dataset 15
CHAPTER THREE RESEARCH DESIGN and METHODOLOGY 18
3.1 The Conceptual Model 18
3.2 Study Design 19
3.3 Population and Sample 21
3.4 Sampling Method 21
3.5 Calculation of Dosage 22
3.8 Limitation of Research 28
CHAPTER FOUR QUANTITATIVE RESULTS 29
4.1. Flow Illustrates The Selection of Populations. 29
4.2 Distribution of Fenofibrate Group 31
4.3 Frequency Distribution and Association of Socio Demography with Fenofibrate 32
4.4 Frequency of Fenofibrate Use 34
CHAPTER FIIVE DISCUSSION 37
REFERENCES 39


[1]Xinzhi Zhang, MD, PhD; Jinan B. Saaddine, MD, MPH; Chiu-Fang Chou, DrPH; Mary Frances Cotch, PhD; Yiling J. Cheng, MD, PhD; Linda S. Geiss, MA; Edward W. Gregg, PhD; Ann L. Albright, PhD, RD; Barbara E. K. Klein, MD, MPH; Ronald Klein, MD, MPH, Prevalence Of Diabetic Retinopathy In The United States, 2005-2008. JAMA, 2010. 304(6): p. 649-56.
[2]Chih-Jen Chang, Feng-Hwa Lu, Yi-Ching Yang, Jin-Shang Wu,Ta-Jen Wu, Muh-Shy Chen, Lee-Ming Chuang, Tong-Yuan Tai. Epidemiologic study of type 2 diabetes in Taiwan. Elsevier 2000. 50 suppl 2: p. S49–S59
[3]C. H. Chang, W.Y.S., Y. D. Jiang, H. Y. Li, T. J. Chang, W. H.-H. Sheu, C. F. Kwok, L. T. Ho and L. M. Chuang, Type 2 Diabetes Prevalence And Incidence Among Adults In Taiwan During 1999–2004: A National Health Insurance Data Set Study. Diabetic Medicine, 2010. 27: p. 1464-5491.
[4]Donald S. Fong, MD, MPH, Lloyd Aiello, MD, PHD, Thomas W. Gardner, MD, George L. King, MD, George Blankenship, MD, Jerry D. Cavallerano, OD, PHD, Fredrick L. Ferris III, MD, Ronald Klein, MD, MPH and for the American Diabetes Association , Retinopathy In Diabetes. Diabetes Care, 2004. 27 Suppl 1: p. S84-7.
[5]Simo, R. and C. Hernandez, Advances In The Medical Treatment Of Diabetic Retinopathy. Diabetes Care, 2009. 32(8): p. 1556-62.
[6]Hermans, M.P., Non-Invited Review: Prevention Of Microvascular Diabetic Complications By Fenofibrate: Lessons From FIELD and ACCORD. Diab Vasc Dis Res, 2011. 8(3): p. 180-9.
[7]Barcelo, A. and S. Rajpathak, Incidence and Prevalence of Diabetes Mellitus in the Americas. Rev Panam Salud Publica, 2001. 10(5): p. 300-8.
[8]Craig, M.E., A. Hattersley, and K.C. Donaghue, Definition, Epidemiology And Classification Of Diabetes In Children And Adolescents. Pediatr Diabetes, 2009. 10 Suppl 12: p. 3-12.
[9]Bindraban Navin,Van Valkengoed Irene,Mairuhu Gideon,Holleman Frits,Hoekstra Joost,Michels Bob,Koopmans Richard,Stronks Karien, Prevalence Of Diabetes Mellitus And The Performance Of A Risk Score Among Hindustani Surinamese, African Surinamese And Ethnic Dutch: A Cross-Sectional Population-Based Study. BMC Public Health, 2008. 8.
[10]Padmaja K Rani, Rajiv Raman, Aditi Gupta, Swakshyar S Pal, Vaitheeswaran Kulothungan and Tarun Sharma, Albuminuria and Diabetic Retinopathy in Type 2 Diabetes Mellitus Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 12). Diabetol Metab Syndr, 2011. 3(1): p. 9.
[11]Patrizio Tatti, Patrizia Di Mauro, Leonardo Masselli, Adriano Longobardi, and Annabel Barber, Prevention Of Diabetic Eye Disease: The Commonest Cause Of Blindness In Individuals Younger Than 65 Years. Clin Ophthalmol, 2010. 4: p. 1291-8.
[12][No authors listed], Reducing Ocular Damage In Type 2 Diabetes: The Field Study Shows Fenofibrate Benefits. Cardiovasc J Afr, 2007. 18(6): p. 400.
[13]Prof AC Keech, FRACP, Prof P Mitchell, FRANZCO, PA Summanen, FEBO, J O'Day, FRANZCO, Prof TME Davis, MRCP, MS Moffit, DipTc, Prof M-R Taskinen, MD, Prof RJ Simes, FRACPa, D Tse, PhDa, E Williamson, PhD, A Merrifield, PhD, Prof LT Laatikainen, FEBO, MC d'Emden, FRACP, DC Crimet, MDl, RL O'Connell, MMedStat, Prof PG Colman, FRACP, for the FIELD study investigators, Effect Of Fenofibrate On The Need For Laser Treatment For Diabetic Retinopathy (Field Study): A Randomised Controlled Trial. Lancet, 2007. 370(9600): p. 1687-97.
[14]Chew, E. Y., Ambrosius, W. T., Davis, M. D., Danis, R. P., Gangaputra, S., Greven, C. M., Hubbard, L., Esser, B. A., Lovato, J. F., Perdue, L. H., Goff, D. C., Jr., Cushman, W. C., Ginsberg, H. N., Elam, M. B., Genuth, S., Gerstein, H. C., Schubart, U., Fine, L. J., Effects Of Medical Therapies On Retinopathy Progression In Type 2 Diabetes. N Engl J Med, 2010. 363(3): p. 233-44.
[15]M M Engelgau, K M Narayan and W H Herman, Screening For Type 2 Diabetes. American Diabetes Association Diabetes Care, 2004. 27 Suppl 1: p. S11-4.
[16]Henry N. Ginsberg, M.D., Marshall B. Elam, M.D., Laura C. Lovato, M.S., John R. Crouse III, M.D., Lawrence A. Leiter, M.D., Peter Linz, M.D., William T. Friedewald, M.D., John B. Buse, M.D., Ph.D., Hertzel C. Gerstein, M.D., Jeffrey Probstfield, M.D., Richard H. Grimm, M.D., Ph.D., Faramarz Ismail-Beigi, M.D., Ph.D., J. Thomas Bigger, M.D., David C. Goff, Jr., M.D., Ph.D., William C. Cushman, M.D., Denise G. Simons-Morton, M.D., Ph.D., and Robert P. Byington, Ph.D. Effects Of Combination Lipid Therapy In Type 2 Diabetes Mellitus. N Engl J Med, 2010. 362(17): p. 1563-74.
[17]Yu-Chun Chen , Hsiao-Yun Yeh, Jau-Ching Wu, Ingo Haschler, Tzeng-Ji Chen, Thomas Wetter. Taiwan’s National Health Insurance Research Database: Administrative Health Care Database As Study Object In Bibliometrics. Springer 2011. 86: p. 365–380.
[18]Michel P Hermans. Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diabetes & Vascular Disease Research 2011. 8(3): p. 180–189.
[19]Emily Loghmani. Contemporary management of adolescents with diabetes mellitus. Part 1: Type 1 diabetes. Adolescent Health Update 2000;12(2), Table 2, p 3.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊
 
1. 從台灣健保資料庫分析第2型糖尿病患者 使用降血脂藥物Fenofibrate後 續發慢性腎臟疾病之研究
2. 人類病毒疣(經由人類乳突病毒引起)可能為年輕患者的風險因子發生乳癌透過關聯性資料採礦
3. 全民健保資料庫之女性乳癌緩解與復發統計分析
4. 低氧培養情況下之幹細胞培養液促進糖尿病大白鼠之血管新生及骨折癒合
5. 應用資料探勘技術於全民健保資料庫-以敗血症為例
6. 台灣地區糖尿病病患及其視網膜病變的醫療資源耗用台灣地區糖尿病病患及其視網膜病變的醫療資源耗用
7. 第二型糖尿病患者胰島素類似物和高血壓藥物使用與危及視力的糖尿病視網膜病變之相關性研究
8. 藉由Connectivity Map研究老藥新用
9. 以非肥胖型基因轉殖糖尿病小鼠模式探討protein tyrosine phosphastase non-receptor type 22 (Ptpn22) 對作用型及調節型T細胞差異性調控之機制及其對自體免疫糖尿病之影響
10. 糖尿病患者服用降血脂藥物與罹患 視網膜病變風險之相關性
11. 探討老人憂鬱與糖尿病風險之關聯並預測新生糖尿病之風險
12. 第二型糖尿病且罹患慢性腎臟病及周邊血管疾病之患者使用cilostazol後是否可以降低足部截肢之風險
13. 葡萄糖及糖化終產物對人類視網膜色素上皮細胞發炎介質及血管新生分子的影響
14. 步行活動介入對第二型糖尿病患者病情控制及生活品質之成效探討
15. 運動處方介入對第二型糖尿病患的心肺功能和運動時血壓之影響